Annual report 2021

Annual report 2021

High-precision delivery

medmix designs, develops, manufactures and delivers innovative high-precision devices and services for the mixing, application and injection of liquids in a wide range of viscosities for the healthcare, consumer and industrial end-markets. On September 30, 2021, medmix spun off from Sulzer. Its shares are since listed and traded on the SIX Swiss Exchange in Zurich (Securities No. 112.967.710/ISIN CH1129677105). This is the first Annual Report of medmix as an independent group of companies. 
Read more about medmix here

Letter to the shareholders 


Our KEY Figures

457.3 m CHF

revenue in 2021

25.0 %

adjusted EBITDA margin

55.6 m CHF

free cash flow generated in 2021

Financial Review Section

medmix strategy: platform for growth


The medmix approach to sustainability